Surescripts

Overview

Surescripts is the dominant operator of the United States’ national health information network for prescription transactions, functioning as the essential plumbing through which the majority of the country’s electronic prescribing activity flows. Founded in 2001 as SureScript Systems by independent pharmacy associations, it merged with RxHub in 2008, consolidating the nascent e-prescribing infrastructure under a single entity.

In October 2024, TPG Capital acquired a majority stake at a ~$1.8 billion valuation (28x projected EBITDA), marking a transition from utility cooperative to for-profit growth platform. Prior shareholders — NCPA, NACDS, Express Scripts, and CVS Caremark — retained equity stakes. The PBM co-ownership structure places the primary buyers and dispensers of pharmaceutical services in control of the connecting infrastructure.

In 2025, the network connected 2.32 million healthcare professionals and processed 30.5 billion total health intelligence transactions (+12% YoY). E-prescription volume reached approximately 2.5 billion prescriptions. The FTC established in a July 2023 consent order that Surescripts maintains a 95% market share (“supershare”) in e-prescribing routing and eligibility.

Services & Capabilities

E-Prescribing Routing and Eligibility

The foundational business. Routes electronic prescriptions from prescriber EHRs to pharmacies and processes insurance eligibility checks. 99% of U.S. population in Master Patient Index. 1.39 million prescribers using e-prescribing (up 4.0% in 2025). EPCS: 84.4% of e-prescribers, 98.3% of pharmacies; 310.5 million EPCS prescriptions in 2024. 99.998% uptime.

Real-Time Prescription Benefit (RTPB)

Delivers patient-specific cost and formulary information at point of prescribing — out-of-pocket cost, lower-cost alternatives, PA requirements. Reached 1 billion uses in 2025 with 900,000+ active prescribers. Average savings: $77 per retail prescription, $817 per specialty prescription when lower-cost alternative accepted. Peer-reviewed data: responses returned for 88% of queries, lower-cost alternatives in 67.2% of alerts, accepted 32% of the time.

Critical pharma implication: RTPB systematically surfaces generic or preferred-brand alternatives before the patient leaves the exam room. Display logic shaped by PBM formulary decisions — meaning CVS Caremark and Express Scripts (co-owners) have inherent influence over what prescribers see.

Electronic Prior Authorization (ePA)

Connects prescribers via EHRs to PBMs and health plans for real-time PA submission and adjudication. 2025: ePA volumes up 19.9% overall, 26.1% for specialty medications. Covers 84% of prescribers, connects to PBMs covering 98% of insured patients.

Touchless Prior Authorization (February 2025): Eliminates manual data entry by auto-matching clinical data against PBM criteria. Median approval time: 18 seconds. 83 medications in scope (up from 40 in 2024). 45,275 prescribers at 20 health systems; 52 health systems onboarding in 2026. 34% fully automated approval rate. Prescriber PA abandonment dropped from 22% to 4%.

CMS Interoperability Rule (CMS-0057-F) requires FHIR-based PA APIs by January 2027 and faster decision timeframes effective January 2026 — structural growth driver.

Clinical Interoperability Services

• Medication History: 12-month fill histories from PBM claims and pharmacy dispensing (including cash-pay). 99%+ population coverage. 86% of responses augmented with additional data in 2025.
• Clinical Direct Messaging: 1.08 million healthcare professionals/orgs using secure messaging (+11.8% in 2025).
• Record Locator and Exchange / QHIN: Designated a Qualified Health Information Network under TEFCA (April 2025), enabling nationwide clinical data exchange beyond prescriptions.
• Sig IQ: ML system converting free-text medication directions to structured format. Augmented 12.7% of e-prescribing transactions and 60% of Medication History responses in 2025.

Competitive Position

Near-Monopoly in E-Prescribing Routing

95% market share confirmed by FTC. Two-sided network effect: pharmacies need the network reaching the most prescribers, and EHR vendors need the network reaching the most pharmacies. FTC found loyalty contracts foreclosed at least 70% of each market. No viable direct competitor in prescription routing today. Change Healthcare (UnitedHealth) — the most credible historical rival — was removed by the 2022 acquisition and 2024 ransomware attack.

ePA and RTPB Competition

More fragmented. CoverMyMeds (McKesson subsidiary) operates a significant ePA platform. However, Surescripts’ leverage derives from owning the routing layer — EHR vendors already connected for routing have strong incentives to use Surescripts for adjacent services.

Infrastructure Dependency for Pharma

Surescripts is infrastructure, not a vendor relationship, for pharma services companies. Implications:

• RTPB surfaces formulary status and alternatives to prescribers in real time — structurally adverse to non-preferred-tier brands
• ePA data represents the most comprehensive dataset on PA friction
• Medication History provides comprehensive adherence/fill-rate information
• Any pharma services vendor integrating with EHRs/pharmacies/PBMs must route through Surescripts or build prohibitively expensive independent connections

Recent Developments

• TPG Acquisition (October 2024): $1.8B valuation at 28x EBITDA. Transition from utility to PE-owned growth platform. CEO Frank Harvey cited expansion into PA automation, data analytics, and M&A.
• FTC Consent Order (July 2023): 20-year prohibition on exclusivity/loyalty contracts requiring >50% transaction share. $39.75M class action settlement fund for pharmacies overcharged on routing fees.
• QHIN Designation (April 2025): Surescripts Health Information Network LLC designated under TEFCA. Expands beyond prescription exchange into broader clinical data sharing.
• Touchless Prior Authorization (February 2025): 18-second median approval. PA abandonment: 22% to 4%. 83 medications; 52 health systems onboarding 2026.
• RTPB 1 Billion Uses (2025): 900,000+ prescriber users. NCPDP standards upgrades deployed.
• FTC Analytical Brief (February 2026): Reexamined Surescripts as precedent for loyalty discounts in two-sided network markets — signaling ongoing regulatory interest.

Financial Profile

Surescripts is privately held; no audited financials. Estimates from TPG transaction disclosures (Axios):

Metric	2024 (Projected)	2025 (Projected)
Net Revenue	~$405M	~$435M
Adjusted EBITDA	~$65M	~$75M
EBITDA Margin	~16%	~17%

Thin EBITDA margins consistent with historical cost-recovery pricing — per-transaction routing fees have decreased 77% since 2009 as volume scaled. Revenue model: transaction-based fees to pharmacies (~$0.10-$0.30/Rx depending on channel), PBMs (eligibility checks), and EHR vendors (incentive payments). Premium services (RTPB, ePA, Touchless PA) generate incremental fees.

Transaction growth: 21.7B (2022) to 23.8B (2023) to 27.2B (2024) to 30.5B (2025) — ~12% CAGR.

Ownership Post-TPG

• TPG Capital: majority (controlling)
• NCPA: minority equity
• NACDS: minority equity
• Express Scripts (Evernorth/Cigna): minority equity
• CVS Caremark (CVS Health): minority equity

PBM co-owners’ continued presence creates governance tension: TPG wants to maximize revenue; PBMs want to keep network costs low. If Surescripts develops products competing with PBM data services, this tension intensifies.

Sources

Primary source: raw/research/08_surescripts.md. Data from Surescripts 2025 Annual Impact Report, FTC filings, Axios, FierceHealthcare, Healthcare Dive, CMS.gov, Mordor Intelligence, AJHP/PMC.